Idorsia Ltd

LSE:0RQE Stock Report

Market Cap: CHF 145.8m

Idorsia Valuation

Is 0RQE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RQE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RQE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RQE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RQE?

Key metric: As 0RQE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RQE. This is calculated by dividing 0RQE's market cap by their current revenue.
What is 0RQE's PS Ratio?
PS Ratio2x
SalesCHF 74.12m
Market CapCHF 145.77m

Price to Sales Ratio vs Peers

How does 0RQE's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RQE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
AVCT Avacta Group
7.9x0.4%UK£170.1m
BVXP Bioventix
14.4xn/aUK£195.7m
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.8x35.2%UK£28.3m
0RQE Idorsia
2x53.8%CHF 145.8m

Price-To-Sales vs Peers: 0RQE is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (7.4x).

Price to Sales Ratio vs Industry

How does 0RQE's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.0x20.7%
0RQE Idorsia
 2x53.8%US$162.93m
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$553.81m
0RQE 2.0xIndustry Avg. 8.0xNo. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.0x37.4%
0RQE Idorsia
 2x15.1%US$162.93m
No more companies

Price-To-Sales vs Industry: 0RQE is good value based on its Price-To-Sales Ratio (2x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0RQE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RQE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: 0RQE is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RQE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 0.74
CHF 1.60
+114.9%
44.5%CHF 2.60CHF 1.00n/a3
Nov ’25CHF 0.96
CHF 1.60
+66.0%
44.5%CHF 2.60CHF 1.00n/a3
Oct ’25CHF 1.54
CHF 1.78
+15.7%
31.9%CHF 2.60CHF 1.00n/a5
Sep ’25CHF 2.17
CHF 1.78
-17.9%
31.9%CHF 2.60CHF 1.00n/a5
Aug ’25CHF 2.56
CHF 1.76
-31.5%
29.6%CHF 2.60CHF 1.00n/a6
Jul ’25CHF 2.09
CHF 1.69
-18.9%
31.1%CHF 2.60CHF 1.00n/a8
Jun ’25CHF 2.53
CHF 1.69
-33.2%
31.1%CHF 2.60CHF 1.00n/a8
May ’25CHF 1.81
CHF 1.72
-4.5%
32.0%CHF 2.60CHF 1.00n/a8
Apr ’25CHF 2.83
CHF 2.10
-25.8%
41.1%CHF 4.00CHF 1.00n/a8
Mar ’25CHF 2.02
CHF 2.07
+2.3%
41.7%CHF 4.00CHF 1.00n/a8
Feb ’25CHF 1.53
CHF 2.07
+35.3%
41.7%CHF 4.00CHF 1.00n/a8
Jan ’25CHF 2.13
CHF 2.07
-2.9%
41.7%CHF 4.00CHF 1.00n/a8
Dec ’24CHF 1.94
CHF 2.63
+35.8%
64.5%CHF 6.50CHF 1.00n/a8
Nov ’24CHF 1.70
CHF 4.24
+149.4%
79.2%CHF 12.00CHF 1.00CHF 0.968
Oct ’24CHF 2.59
CHF 6.38
+146.1%
36.3%CHF 12.00CHF 4.00CHF 1.548
Sep ’24CHF 5.00
CHF 6.28
+25.5%
35.1%CHF 12.00CHF 4.00CHF 2.179
Aug ’24CHF 6.66
CHF 5.79
-13.2%
13.1%CHF 6.50CHF 4.20CHF 2.567
Jul ’24CHF 6.45
CHF 10.91
+69.1%
62.8%CHF 30.00CHF 6.00CHF 2.0910
Jun ’24CHF 7.99
CHF 13.72
+71.8%
57.0%CHF 30.00CHF 7.00CHF 2.539
May ’24CHF 8.59
CHF 13.46
+56.7%
56.6%CHF 30.00CHF 6.00CHF 1.8110
Apr ’24CHF 10.02
CHF 15.23
+52.1%
39.7%CHF 30.00CHF 9.00CHF 2.8311
Mar ’24CHF 12.70
CHF 15.23
+20.0%
39.7%CHF 30.00CHF 9.00CHF 2.0211
Feb ’24CHF 15.50
CHF 17.43
+12.4%
39.2%CHF 36.00CHF 10.00CHF 1.5311
Jan ’24CHF 13.42
CHF 18.17
+35.4%
39.1%CHF 36.00CHF 10.00CHF 2.1311
Dec ’23CHF 14.36
CHF 19.65
+36.9%
35.0%CHF 36.00CHF 10.00CHF 1.9411
Nov ’23CHF 16.04
CHF 19.71
+22.9%
34.8%CHF 36.00CHF 10.00CHF 1.7010

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€821.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

hVIVO

UK£155.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%